Pursuant to Regulation 30 read with Clause 7 of Para A of Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Abbott India has informed that Sandeep Reddy - Commercial Director - Women’s Health, Metabolics and International Business has tendered his resignation from employment of the Company with effect from June 5, 2024, to pursue an opportunity outside the Company. Pursuant to his resignation, he will also cease to be the Senior Management Personnel of the Company effective the said date. The details required to be disclosed as per SEBI Circular No. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023 is enclosed. Pursuant to Regulation 30 read with Clause 7C of Para A of Part A of Schedule Ill of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the letter of resignation of Sandeep Reddy along with detailed reasons shall be shared separately within seven days from the date the resignation comes into effect.
The above information is a part of company’s filings submitted to BSE.
